Erik L. Brincks

1.4k total citations
25 papers, 1.1k citations indexed

About

Erik L. Brincks is a scholar working on Immunology, Epidemiology and Molecular Biology. According to data from OpenAlex, Erik L. Brincks has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 8 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in Erik L. Brincks's work include Immune Cell Function and Interaction (11 papers), Immune Response and Inflammation (6 papers) and interferon and immune responses (4 papers). Erik L. Brincks is often cited by papers focused on Immune Cell Function and Interaction (11 papers), Immune Response and Inflammation (6 papers) and interferon and immune responses (4 papers). Erik L. Brincks collaborates with scholars based in United States, Netherlands and Canada. Erik L. Brincks's co-authors include Thomas S. Griffith, Tamara A. Kucaba, Kevin L. Legge, David L. Woodland, Arna Katewa, Stewart Sell, Marcia A. Blackman, Jacob E. Kohlmeier, Tres Cookenham and Alan D. Roberts and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Immunology and Cancer Research.

In The Last Decade

Erik L. Brincks

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik L. Brincks United States 18 724 343 319 180 101 25 1.1k
Gerhard Wingender United States 19 1.2k 1.7× 280 0.8× 189 0.6× 281 1.6× 84 0.8× 31 1.6k
Wai Po Chong China 20 748 1.0× 249 0.7× 277 0.9× 161 0.9× 265 2.6× 35 1.3k
Sara L. Colpitts United States 16 490 0.7× 365 1.1× 126 0.4× 126 0.7× 74 0.7× 20 867
Kiva Brennan Ireland 14 618 0.9× 351 1.0× 166 0.5× 135 0.8× 71 0.7× 26 1.1k
Solenne Vigne Switzerland 18 904 1.2× 338 1.0× 132 0.4× 185 1.0× 78 0.8× 30 1.4k
Chang Song United States 16 476 0.7× 190 0.6× 144 0.5× 103 0.6× 60 0.6× 23 797
Louise Swainson United States 15 657 0.9× 235 0.7× 164 0.5× 137 0.8× 172 1.7× 20 1.1k
Anthony E. Zamora United States 15 607 0.8× 215 0.6× 127 0.4× 381 2.1× 72 0.7× 33 952
Rong Ou United States 12 677 0.9× 213 0.6× 173 0.5× 134 0.7× 178 1.8× 20 877
Yvonne Bordon United States 12 549 0.8× 348 1.0× 103 0.3× 238 1.3× 69 0.7× 235 1.1k

Countries citing papers authored by Erik L. Brincks

Since Specialization
Citations

This map shows the geographic impact of Erik L. Brincks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik L. Brincks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik L. Brincks more than expected).

Fields of papers citing papers by Erik L. Brincks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik L. Brincks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik L. Brincks. The network helps show where Erik L. Brincks may publish in the future.

Co-authorship network of co-authors of Erik L. Brincks

This figure shows the co-authorship network connecting the top 25 collaborators of Erik L. Brincks. A scholar is included among the top collaborators of Erik L. Brincks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik L. Brincks. Erik L. Brincks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zakharia, Yousef, Robert R. McWilliams, Olivier Rixe, et al.. (2021). Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. Journal for ImmunoTherapy of Cancer. 9(6). e002057–e002057. 70 indexed citations
2.
Kumar, Sanjeev, Firoz A. Jaipuri, Jesse P. Waldo, et al.. (2020). Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. European Journal of Medicinal Chemistry. 198. 112373–112373. 33 indexed citations
3.
Brincks, Erik L., James Truslow Adams, Lifu Wang, et al.. (2020). Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1. Oncotarget. 11(25). 2438–2461. 26 indexed citations
4.
Murphy, Katherine A., Britnie R. James, Frances V. Sjaastad, et al.. (2018). Cutting Edge: Elevated Leptin during Diet-Induced Obesity Reduces the Efficacy of Tumor Immunotherapy. The Journal of Immunology. 201(7). 1837–1841. 46 indexed citations
5.
Brincks, Erik L., James Truslow Adams, Michael Essmann, et al.. (2018). Abstract 3753: Indoximod modulates AhR-driven transcription of genes that control immune function. Cancer Research. 78(13_Supplement). 3753–3753. 8 indexed citations
6.
Brincks, Erik L., Tamara A. Kucaba, Britnie R. James, et al.. (2015). Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma. FEBS Journal. 282(24). 4747–4765. 15 indexed citations
7.
Rodrigue‐Gervais, Ian Gaël, Katherine Labbè, Maryse Dagenais, et al.. (2014). Cellular Inhibitor of Apoptosis Protein cIAP2 Protects against Pulmonary Tissue Necrosis during Influenza Virus Infection to Promote Host Survival. Cell Host & Microbe. 15(1). 23–35. 132 indexed citations
8.
Sell, Stewart, Ian Guest, K. Kai McKinstry, et al.. (2014). Intraepithelial T-Cell Cytotoxicity, Induced Bronchus-Associated Lymphoid Tissue, and Proliferation of Pneumocytes in Experimental Mouse Models of Influenza. Viral Immunology. 27(10). 484–496. 10 indexed citations
9.
James, Britnie R., Erik L. Brincks, Tamara A. Kucaba, Louis Boon, & Thomas S. Griffith. (2014). Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells. Cancer Immunology Immunotherapy. 63(7). 685–697. 17 indexed citations
10.
James, Britnie R., Kristin G. Anderson, Erik L. Brincks, et al.. (2014). CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunology Immunotherapy. 63(11). 1213–1227. 30 indexed citations
11.
Brincks, Erik L., Michael Risk, & Thomas S. Griffith. (2013). PMN and anti-tumor immunity—The case of bladder cancer immunotherapy. Seminars in Cancer Biology. 23(3). 183–189. 34 indexed citations
12.
Steinwede, Kathrin, Jennifer Bohling, Regina Maus, et al.. (2012). TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. The Journal of Experimental Medicine. 209(11). 1937–1952. 76 indexed citations
13.
Brincks, Erik L., Prajwal Gurung, Ryan A. Langlois, et al.. (2011). The Magnitude of the T Cell Response to a Clinically Significant Dose of Influenza Virus Is Regulated by TRAIL. The Journal of Immunology. 187(9). 4581–4588. 32 indexed citations
14.
Kohlmeier, Jacob E., William W. Reiley, Georgia Perona‐Wright, et al.. (2011). Inflammatory chemokine receptors regulate CD8 T cell contraction and memory generation following infection (150.3). The Journal of Immunology. 186(1_Supplement). 150.3–150.3. 5 indexed citations
15.
Brincks, Erik L. & David L. Woodland. (2010). Novel roles for IL-15 in T cell survival. F1000 Biology Reports. 2. 67–67. 21 indexed citations
16.
Griffith, Thomas S., et al.. (2009). TRAIL Gene Therapy: From Preclinical Development to Clinical Application. Current Gene Therapy. 9(1). 9–19. 70 indexed citations
17.
Brincks, Erik L., Arna Katewa, Tamara A. Kucaba, Thomas S. Griffith, & Kevin L. Legge. (2008). CD8 T Cells Utilize TRAIL to Control Influenza Virus Infection. The Journal of Immunology. 181(7). 4918–4925. 153 indexed citations
18.
Brincks, Erik L., Arna Katewa, Tamara A. Kucaba, Thomas S. Griffith, & Kevin L. Legge. (2008). CD8 T cells utilize TRAIL to control influenza virus infection (Journal of Immunology (2008) 181, (4918-4925)). The Journal of Immunology. 181(10). 1 indexed citations
19.
Brincks, Erik L., Tamara A. Kucaba, Kevin L. Legge, & Thomas S. Griffith. (2008). Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells. Human Immunology. 69(10). 634–646. 21 indexed citations
20.
Sanger, Michael J., et al.. (2001). A Comparison of Secondary Chemistry Courses and Chemistry Teacher Preparation Programs in Iowa and Saint Petersburg, Russia. Journal of Chemical Education. 78(9). 1275–1275. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerhard Wingender Breakdown of academic impact, for papers by Wai Po Chong Breakdown of academic impact, for papers by Sara L. Colpitts Breakdown of academic impact, for papers by Kiva Brennan Breakdown of academic impact, for papers by Solenne Vigne Breakdown of academic impact, for papers by Chang Song Breakdown of academic impact, for papers by Louise Swainson Breakdown of academic impact, for papers by Anthony E. Zamora Breakdown of academic impact, for papers by Rong Ou Breakdown of academic impact, for papers by Yvonne Bordon
Rankless by CCL
2026